How Long Does Wegovy Stay in Your System? Clearance, Appetite Return, and the Regain Trajectory

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited

Key Takeaways

• Wegovy uses the same active ingredient (semaglutide) as Ozempic; the half-life of approximately 7 days and 35-day clearance window are identical
• The higher Wegovy dose (2.4 mg) produces higher steady-state concentrations during use but does not change the rate at which drug clears after stopping
• Appetite suppression fades gradually over 2 to 6 weeks after the last dose; full return to baseline appetite usually takes 6 to 8 weeks
• STEP 4 trial data showed mean regain of approximately two-thirds of lost weight over 48 weeks after switching from semaglutide to placebo
• The chronic medication framing matters: weight loss preserved during use is at risk during clearance unless active maintenance behaviors are in place

Direct answer

Wegovy stays in your system for approximately 35 days after the last dose. The active ingredient is semaglutide, which has a 7-day half-life. By 5 half-lives (about 35 days), roughly 97 percent of the drug has been eliminated. Trace amounts may persist for 6 to 8 weeks but at concentrations too low to produce meaningful clinical effect. The clearance is identical to Ozempic because the molecule is the same.

Table of contents

1. The Wegovy half-life and what it predicts
2. Why Wegovy and Ozempic clear at the same rate
3. The 35-day clearance window
4. The appetite return curve after stopping
5. The STEP 4 regain pattern
6. What survives drug clearance
7. Switching from Wegovy to another medication
8. Surgery and procedure planning
9. Pregnancy timing
10. Decision framework before stopping
11. Contrary view: maybe stopping isn't the point
12. FAQ
13. Sources

The Wegovy half-life and what it predicts

Wegovy's elimination half-life is approximately 165 to 184 hours, or roughly 7 days. This is the same value reported for Ozempic and for compounded semaglutide products because all three contain the same active ingredient.

The half-life predicts three things:

• How fast the drug clears after stopping (5 half-lives, ~35 days for clinical clearance)
• How long it takes to reach steady state at a new dose during titration (~4 to 5 weeks)
• How stable plasma concentration is across the weekly dosing interval (relatively stable, given the 7-day half-life matches the 7-day dosing interval)

None of these depend on the specific Wegovy dose. The 2.4 mg maintenance dose has the same half-life as the 0.25 mg starting dose; only the absolute concentration differs.

Why Wegovy and Ozempic clear at the same rate

Wegovy and Ozempic are different brand products with different FDA-approved indications and different dose ranges, but they contain the same molecule: semaglutide.

Pharmacokinetic properties depend on the molecule:

• Wegovy 2.4 mg: 7-day half-life
• Wegovy 1.7 mg: 7-day half-life
• Wegovy 1 mg: 7-day half-life
• Ozempic 2 mg: 7-day half-life
• Ozempic 1 mg: 7-day half-life
• Ozempic 0.5 mg: 7-day half-life
• Compounded semaglutide at any dose: 7-day half-life

Dose affects how much drug is in circulation at steady state, not how fast a given amount clears. A patient on Wegovy 2.4 mg has more drug in circulation than a patient on Ozempic 1 mg, but the same fraction (50 percent) of that drug clears each week.

The 35-day clearance window

Time after last dose	Half-lives	Drug remaining
7 days	1	~50%
14 days	2	~25%
21 days	3	~12.5%
28 days	4	~6.25%
35 days	5	~3%
42 days	6	~1.5%
49 days	7	~0.8%

By day 35, drug levels are typically too low to produce meaningful clinical effect. By day 49, the drug is essentially gone for all practical purposes. The 35-day figure is the standard clearance threshold; the 49-day figure provides margin for conservative timing decisions.

The appetite return curve after stopping

Appetite suppression fades on a curve that roughly tracks drug concentration:

Week 1. Drug at full steady-state level; appetite typically still suppressed; many patients describe little perceived change in week one.

Week 2 to 3. Drug declining to 25-50 percent of steady state; appetite beginning to return for sensitive patients; food noise may resurface intermittently.

Week 4 to 5. Drug at 6-12 percent of steady state; substantial appetite return for most patients; meal sizes drift upward; cravings return for previously dampened foods.

Week 6 to 8. Drug essentially gone; appetite at or near pre-medication baseline; full return of pre-treatment eating patterns unless active intervention prevents it.

Individual variation is substantial. Some patients describe abrupt appetite return at weeks 3 to 4; others describe gradual fade over 8 to 12 weeks. The pharmacokinetic curve sets the average; personal experience varies around it.

The STEP 4 regain pattern

STEP 4 (Rubino et al., JAMA 2021) is the most directly relevant trial for understanding what happens after Wegovy stops. The trial enrolled patients who had completed a 20-week titration to semaglutide 2.4 mg and lost an average of 10.6 percent of body weight. Half were randomized to continued semaglutide; half to placebo.

By week 68 (48 weeks after randomization to placebo or continued treatment):

• Continued semaglutide arm: additional weight loss of approximately 7.9 percent (total loss approximately 17.4 percent from baseline)
• Placebo arm: weight regain of approximately 6.9 percent (total loss approximately 5.0 percent from baseline)

The placebo arm regained roughly two-thirds of their initial loss. The regain was steepest in the first 8 to 16 weeks and slowed but did not stop through week 68. By the end of the trial, the placebo arm was still trending toward additional regain.

This is the central practical fact about stopping Wegovy: without continued medication or substantial behavioral intervention, regain is the typical outcome.

What survives drug clearance

Some effects of Wegovy treatment can persist after the drug clears:

• Behavioral patterns learned during treatment (smaller portions, less snacking, more attention to nutrition)
• Improved insulin sensitivity from weight loss (partially persists if weight loss is partially maintained)
• Improved cardiovascular markers (often persist for months)
• Some metabolic adaptations that may persist long-term

What does not persist:

• The medication's direct appetite-suppressing effect
• The slowed gastric emptying
• The pharmacologic glucose effects beyond what weight loss alone produces
• The neural quieting of food noise (this typically returns as the drug clears)

Switching from Wegovy to another medication

Common transitions and timing:

Switch to	Washout	Notes
Zepbound (tirzepatide)	None typically	Start on next scheduled dose day; choose tirzepatide starting dose based on weight loss goals and prior tolerance
Ozempic (lower-dose semaglutide)	None	Same molecule at lower dose; transition is mostly a dose reduction
Compounded semaglutide	None	Same molecule from different source; verify dose translation accurately
Oral semaglutide	1-2 weeks recommended	Different absorption profile; clearer baseline helpful for evaluating oral dosing

Surgery and procedure planning

The 2024 ASA guidance applies the same way to Wegovy as to Ozempic and all other GLP-1 medications:

• Elective procedures requiring fasting: hold for at least 7 days
• Higher-risk procedures: consider holds of 14 to 28 days
• Emergency procedures: proceed with full-stomach precautions

For Wegovy specifically, the 7-day minimum represents one half-life. About 50 percent of the drug remains at this point. For most procedures the risk is acceptable; for high-risk procedures, longer holds reflect the actual clearance math better.

Pregnancy timing

FDA labeling and ACOG guidance recommend discontinuing semaglutide at least 2 months before planned conception. The 2-month figure provides margin beyond the 35-day standard clearance:

• 5 half-lives (35 days): standard clinical clearance threshold
• 2 months (~60 days): approximately 8.5 half-lives; drug essentially gone
• 3 months (~90 days): very conservative margin

The conservative timing reflects limited human safety data in pregnancy and animal studies showing fetal effects at high doses. Reliable contraception during Wegovy treatment is recommended for patients of reproductive potential.

Patients planning pregnancy should discuss the transition with the prescriber well in advance.

Decision framework before stopping

Questions to consider before discontinuing Wegovy:

• Is the goal a permanent stop or a transition to another medication?
• What's the maintenance plan to preserve weight loss?
• How much regain is acceptable, and what's the action point if regain exceeds that?
• What other health benefits have improved during treatment (sleep apnea, joint pain, fatty liver, glucose control), and how will those be monitored if they worsen with regain?
• Could cost or access barriers be addressed differently (insurance appeal, compounded version, savings program) before stopping entirely?

The decision is rarely strictly about whether to stop the medication. It's about what comes next.

Contrary view: maybe stopping isn't the point

The framing of "how long does Wegovy stay in your system" implies that the patient is or will be stopping. For many patients, this is the wrong framing.

Obesity treatment guidelines from the American Association of Clinical Endocrinology, the Endocrine Society, and the American Diabetes Association increasingly position obesity as a chronic disease requiring ongoing management. The STEP 5 trial (Garvey et al., Nature Medicine 2022) showed sustained weight loss of approximately 15 percent over two years on continuous semaglutide. STEP 4 showed regain on discontinuation.

Within this framing, the question "how long until Wegovy clears so I can be done with it" reflects a misunderstanding. The medication is producing the benefit; stopping the medication is stopping the benefit. The fact that the drug clears in 35 days is not a feature; it's a constraint that gets in the way of pregnancy planning and surgery but is otherwise mostly irrelevant to the patient's interests.

This is not an argument that no one should ever stop Wegovy. Some patients tolerate the medication poorly. Some can sustain weight loss through aggressive lifestyle management. Some have completed a defined treatment goal and reasonably want to come off. But the question "how long stays in my system" is often the wrong question; "how do I sustain the benefit" is usually more useful.

FAQ

What is the short answer for How Long Does Wegovy Stay in Your System? Clearance, Appetite Return, and the Regain Trajectory?

Wegovy stays in your system for approximately 35 days after the last dose. The active ingredient is semaglutide, which has a 7-day half-life. By 5 half-lives (about 35 days), roughly 97 percent of the drug has been eliminated. Trace amounts may persist for 6 to 8 weeks but at concentrations too low to produce meaningful clinical effect. The clearance is identical to Ozempic because the molecule is the same.

What should patients track during the first few weeks?

Track dose date, appetite change, weight trend, nausea, bowel habits, hydration, sleep, and any symptom that changes after a dose increase.

When should the prescriber be involved?

Contact the prescribing clinician if symptoms are severe, persistent, worsening after titration, or paired with dehydration, abdominal pain, vomiting, low blood sugar, or medication-timing confusion.

Does this replace the medication label?

No. Use the FDA label, pharmacy instructions, and your prescriber's written plan first. This page explains the timing pattern behind how long does wegovy stay in your system.

Why do timelines vary between patients?

Timelines vary because dose escalation, starting weight, diabetes status, other medications, food intake, gastric emptying, and side-effect sensitivity differ from person to person.

What is the safest way to use this information?

Use it to set expectations and ask better questions, not to change a dose, skip a dose, restart after a break, or combine medications without medical guidance.

Related guides

• How Long Does Semaglutide Stay in Your System? The Same Molecule, the Same Clearance
• How Long Does Mounjaro Stay in Your System? Clearance, Glucose, and Diabetes Care After Stopping
• How Long Does Ozempic Stay in Your System? The Half-Life Math, Plainly Stated
• How Long Does Zepbound Stay in Your System? The 5-Day Half-Life and What It Means
• How Long Does Tirzepatide Stay in Your System? The Molecule Is the Molecule
• How Long Does Tirzepatide Take to Suppress Appetite? Mapping the Food Noise Drop

Sources

1. Rubino D, et al. STEP 4. JAMA. 2021;325(14):1414-1425.
2. Wilding JPH, et al. STEP 1. N Engl J Med. 2021;384(11):989-1002.
3. Garvey WT, et al. STEP 5. Nature Medicine. 2022;28:2083-2091.
4. Lincoff AM, et al. SELECT. N Engl J Med. 2023;389:2221-2232.
5. Lau J, et al. Discovery of semaglutide. J Med Chem. 2015;58(18):7370-7380.
6. Knudsen LB, Lau J. Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol. 2019;10:155.
7. FDA. Wegovy Prescribing Information. Updated 2024.
8. American Society of Anesthesiologists. Multisociety GLP-1 Statement. 2024.
9. ACOG Committee Opinion. Medications and Pregnancy Planning. 2024.
10. Endocrine Society. Pharmacological Management of Obesity. 2023.
11. American Diabetes Association. Standards of Care in Diabetes. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a telehealth platform that connects patients with independent licensed clinicians. The content here is educational and is not a substitute for individualized clinical care.

Compounded Medication Notice. Compounded semaglutide dispensed through FormBlends is prepared by 503A pharmacies. It is not FDA-approved and is not therapeutically equivalent to brand Wegovy or Ozempic.

Results Disclaimer. Trial figures including STEP 4 regain percentages reflect mean results in trial populations. Individual experience varies. Personal regain trajectories depend heavily on behavioral patterns after stopping.

Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends has no affiliation with these companies.